PLSE - Pulse Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
15.58
+0.02 (+0.13%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close15.56
Open15.38
Bid15.18 x 800
Ask17.48 x 800
Day's Range15.38 - 15.80
52 Week Range8.60 - 22.20
Volume27,617
Avg. Volume66,058
Market Cap322.668M
Beta (3Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-2.20
Earnings DateMar 12, 2018 - Mar 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.00
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    Pulse Biosciences to Report First Quarter 2019 Operational Highlights and Financial Results

    Pulse Biosciences, Inc. , a novel medical therapy company bringing to market its proprietary CellFX™ System today announced that the Company will report first quarter 2019 operational highlights and financial results on Tuesday, April 30, 2019.

  • Business Wire4 days ago

    Pulse Biosciences Grants Equity Incentive Awards to New Employees

    Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ System, announced today that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 28,000 shares of Pulse Biosciences common stock to three new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on April 15, 2019. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual’s entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).

  • Business Wire24 days ago

    Pulse Biosciences Announces Presentations at the 2019 American Society for Laser Medicine and Surgery Annual Conference

    Pulse Biosciences, Inc. , a novel medical therapy company bringing to market its proprietary CellFX™ System, today announced that key findings from its clinical programs using Nano-Pulse Stimulation™ technology will be presented at the American Society for Laser Medicine and Surgery’s Annual Conference being held March 27-31, 2019, in Denver, CO.

  • Business Wirelast month

    Pulse Biosciences Appoints Mitchell Levinson to Board of Directors

    Pulse Biosciences, Inc.(PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ System, today announced the appointment of Mitchell Levinson to its board of directors. In connection with his appointment to the board, Mr. Levinson will also serve as a member of the audit committee. Levinson, 58, has more than 25 years of experience bringing novel medical technologies to the market, including over a decade in the aesthetics procedure market.

  • Business Wire2 months ago

    Pulse Biosciences Announces Late Breaking Oral Presentation of Sebaceous Hyperplasia Study Results at the 2019 AAD Annual Meeting

    Pulse Biosciences’ patented Nano-Pulse Stimulation™ technology (“NPS™”), delivered by its proprietary, tunable CellFX System, is characterized by the delivery of a series of nanosecond duration electrical energy pulses, with pulse durations from billionths up to a millionth of a second.

  • Business Wire2 months ago

    Pulse Biosciences Submits 510(K) to U.S. FDA for CellFX™ System

    Pulse Biosciences, Inc. (PLSE), a novel medical therapy company bringing to market its proprietary CellFX™ System today announced the Premarket Notification 510(k) submission to the U.S. Food and Drug Administration (FDA) for its CellFX System. The Company’s FDA filing requests clearance of the CellFX System for commercial use in common dermatologic procedures to remove general benign lesions including sebaceous hyperplasia (SH), a common but difficult to treat facial lesion and seborrheic keratosis (SK), the most common benign raised pigmented lesion. Pursuant to Section 510(k), once the application has been accepted, the FDA will conduct its substantive review and may request additional information from the Company based on that review.

  • Pulse Biosciences, Inc. (PLSE) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Pulse Biosciences, Inc. (PLSE) Q4 2018 Earnings Conference Call Transcript

    PLSE earnings call for the period ending December 31, 2018.

  • Business Wire2 months ago

    Pulse Biosciences Quarterly Investor Conference Call

    First patient treated in the CellFX™ back acne clinical feasibility study

  • Business Wire3 months ago

    Pulse Biosciences to Report Fourth Quarter and Full Year 2018 Operational Highlights and Financial Results

    Pulse Biosciences, Inc. , a novel medical therapy company bringing to market its proprietary CellFX™ System today announced that the Company will report fourth-quarter and full-year 2018 operational highlights and financial results on Thursday, February 7, 2019.

  • Business Wire3 months ago

    Pulse Biosciences Announces Two Appointments Focused on CellFX™ Commercialization: Promotion of Edward Ebbers and Addition of Robert Tyson

    Pulse Biosciences, Inc. (PLSE), a medical technology company bringing to market its proprietary CellFX™ System, today announced the promotion of Edward Ebbers to Executive Vice President and General Manager, Dermatology, and the addition of Robert Tyson as Vice President of Sales, North America. The leadership pair brings more than 35 years of combined experience commercializing novel technologies in the aesthetic dermatology market and the necessary skillsets to launch and scale the CellFX System and its growing pipeline of applications into the aesthetic dermatology market.

  • Business Wire3 months ago

    Pulse Biosciences Announces Positive Clinical Results of Its Nano-Pulse Stimulation™ Technology Platform to Treat Patients with Sebaceous Hyperplasia Lesions on the Face

    Pulse Biosciences, Inc. (PLSE) today announced positive results from its clinical efficacy study using proprietary Nano-Pulse Stimulation™ (NPS™) technology to treat patients with Sebaceous Hyperplasia (SH), a difficult-to-treat skin condition that typically presents on the face. Initial data indicate that 221 of 222 (99.5%) facial SH lesions treated with NPS energy were rated as clear or mostly clear by clinical investigators 60 days post treatment. NPS is a non-thermal technology that utilizes ultra-short, nanosecond energy pulses that directly interacts with the physical structure of cells without disrupting the integrity of non-cellular tissues.

  • How Many Insiders Bought Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares?
    Simply Wall St.4 months ago

    How Many Insiders Bought Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...

  • Business Wire4 months ago

    Pulse Biosciences, Inc. Announces Closing of Its $45 Million Rights Offering

    Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, announced today that its rights offering has closed. The rights offering resulted in the issuance of 3,581,148 shares of the Company’s common stock at a price of $12.5658 per share for total gross proceeds of $45 million to the Company. Investors who have participated in the rights offering should expect to see the shares issued to them in book-entry or, uncertificated, form.

  • GlobeNewswire4 months ago

    Investor Expectations to Drive Momentum within eBay, Pulse Biosciences, Evolus, Weibo, OptiNose, and The Descartes Systems Group — Discovering Underlying Factors of Influence

    NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire4 months ago

    Pulse Biosciences, Inc. Announces Oversubscription, Pricing and Preliminary Results for Its $45 Million Rights Offering

    Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, today announced the completion of its rights offering, which expired at 5:00 p.m. Eastern Time on December 6, 2018 (the “Expiration Date”). In accordance with the pricing structure of the rights offering described in the prospectus relating to the offering, Pulse Biosciences has determined that the final subscription price per share for the shares offered in the rights offering is $12.5658 per share, which is the volume weighted average price of the Company’s common stock as calculated for the five-trading day period through and including the Expiration Date.

  • Business Wire5 months ago

    Pulse Biosciences, Inc. Announces Commencement of Rights Offering

    Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, today announced that it has commenced its previously announced rights offering of $45,000,000 of its common stock. The subscription rights will expire and have no value if they are not exercised prior to 5:00 p.m. Eastern Time on Thursday December 6, 2018 (the “Expiration Date”). Pursuant to the rights offering, Pulse Biosciences is distributing, at no charge to the holders of its common stock, non-transferable subscription rights to purchase up to $45,000,000 of shares of its common stock at a subscription price per share equal to the lesser of (i) $13.33 per share (the “Initial Price”) or (ii) the volume weighted average price (the “Alternate Price”) of the Company’s common stock as calculated for the five-trading day period through and including the Expiration Date.

  • Business Wire5 months ago

    Pulse Biosciences, Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of Its Registration Statement

    Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ Nano-Pulse Stimulation™ (NPS™) platform, today announced that it has set key dates and pricing structure for its previously announced rights offering of $45,000,000 of its common stock. Pulse Biosciences intends to issue non-transferable subscription rights to purchase shares of its common stock to common stockholders as of 5:00 p.m. Eastern Time on Monday November 19, 2018 (the “Record Date”).

  • GlobeNewswire6 months ago

    Report: Developing Opportunities within Pulse Biosciences, Baxter International, FirstEnergy, Affiliated Managers Group, Baidu, and Shopify — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire6 months ago

    Pulse Biosciences Files Registration Statement for Rights Offering

    Pulse Biosciences, Inc. (PLSE) (the “Company”, or “Pulse Biosciences”) today announced that it filed a registration statement on Form S-3 with the Securities and Exchange Commission (the “SEC”) for a rights offering to its existing stockholders. The rights offering will be made through the distribution of non-transferable subscription rights to purchase shares of the Company’s common stock, par value $0.001 per share, at a subscription price to be determined. Assuming the rights offering is fully subscribed, the Company will receive gross proceeds of approximately $45 million, less expenses of the rights offering.